What is Evolus's market cap?

Evolus (EOLS) has a market capitalization of $407.0M and trades on NASDAQ.

What is Evolus's revenue and profitability?

Evolus generated $301.8M in trailing twelve-month revenue with a net loss of $43.6M, representing a net margin of -14.4%. Gross margin stands at 66.1%, with free cash flow of -$67.4M. These figures are based on the Q1 2026 filing.

Who are Evolus's competitors?

Evolus's key competitors include AbbVie. These companies compete in similar markets and product categories.

Who does Evolus partner with?

Evolus's notable partners include Daewoong Pharmaceuticals Co. Ltd., Symatese Aesthetics S.A.S., Medytox, Inc..

Where is Evolus headquartered?

Evolus is headquartered in United States of America and employs approximately 279 people. It has been publicly traded since 2018.

Evolus

EOLS

Evolus, Inc. is a performance beauty company focused on the cash-pay medical aesthetics market.

Market cap

$406.98M-29.6%

Revenue$301.8M+9.6%

Net income-$43.6M+22.5%

Free cash flow-$67.4M-183%

EPS (diluted)-$0.67+23.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$73.1MBeat by $616.1K EPS-$0.10Beat by $0.04

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$81.5M

EPS estimate-$0.01

Financials

Q1 2026

Income statement

See full

Revenue$73.1M+6.7%

Gross profit$48.9M+4.8%

Operating income-$6.8M+54.9%

Net income-$10.7M+43.5%

EPS (diluted)-$0.16+46.7%

Balance sheet

See full

Cash & equivalents$49.8M-26.7%

Total debt$164.9M-4.1%

Total equity-$28.8M-336%

Total assets$220.6M+3.4%

Cash flow

See full

Operating cash flow-$10.0M+36.3%

CapEx$415.0K+30.1%

Free cash flow-$10.4M+35.0%

Valuation & ratios

Valuation

See full

Market cap$406.98M-29.6%

Enterprise value$522.09M-23.6%

P/S1.4×-0.8×

Profitability

See full

Gross margin66.1%-2.4pp

Net margin-14.4%-3.3pp

Returns & leverage

See full

Current ratio2×-0.3×

Segments

By product

See full

Jeuveau$66.0M-3.0%

Evolysse$6.7M—

Service revenue$390.0K-12.9%

By segment

See full

Reportable Segment$73.1M+6.7%

Competitors

By market cap

AbbVie$453.91B+36.3%

Evolus$407.0M-32.0%

By revenue growth

Evolus+9.6%

AbbVie+9.5%

By net margin

AbbVie5.79%-1.5pp

Evolus-14.43%+6.0pp

Profile

Evolus, Inc. is a performance beauty company focused on the cash-pay medical aesthetics market. The company specializes in the commercialization of injectable neurotoxins and hyaluronic acid (HA) gels, targeting aesthetic practitioners through a customer-centric, digital-first approach. By pursuing an aesthetic-only strategy without seeking therapeutic indications, the company maintains greater marketing and pricing flexibility.

Competitive position

Evolus differentiates itself as the only U.S. company with an aesthetic-only neurotoxin, leveraging a digital platform and consumer loyalty programs to compete against larger diversified pharmaceutical firms.

GeographiesUnited States, Canada, European Union, Australia, United Kingdom

Customer segmentsAesthetic practitioners, Medical spas, Dermatology clinics

Business modelDirect-to-practitioner sales, Licensing and distribution, B2B2C

SuppliersContract manufacturing organizations, Biopharmaceutical research and development, Raw material suppliers for HA gels

CustomersLicensed aesthetic practitioners, Medical clinics, Self-pay consumers

CountryUnited States of America

Listed2018

Employees279.0

CEODavid Moatazedi

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteevolus.com

FilingsSEC EDGAR

Ask your AI about Evolus.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evolus's market cap?: Evolus (EOLS) has a market capitalization of $407.0M and trades on NASDAQ.
What is Evolus's revenue and profitability?: Evolus generated $301.8M in trailing twelve-month revenue with a net loss of $43.6M, representing a net margin of -14.4%. Gross margin stands at 66.1%, with free cash flow of -$67.4M. These figures are based on the Q1 2026 filing.
Who are Evolus's competitors?: Evolus's key competitors include AbbVie. These companies compete in similar markets and product categories.
Who does Evolus partner with?: Evolus's notable partners include Daewoong Pharmaceuticals Co. Ltd., Symatese Aesthetics S.A.S., Medytox, Inc..
Where is Evolus headquartered?: Evolus is headquartered in United States of America and employs approximately 279 people. It has been publicly traded since 2018.